Stability indicating validated RP-HPLC method for Simultaneous estimation of Elbasvir and Grazopravir in Bulk and Pharmaceutical Dosage form

• Published in: Research journal of pharmacy and technology 2020-02, Vol.13 (2), p.950-955
• Main Authors: Thoddi, Parthasarathi, Gautam, Girendra Kumar, BH, CH Narasimha Raju
• Format: Article
• Language: English
• Subjects: Accuracy; Caustic soda; Chromatography; Hepatitis; Hydrochloric acid; Methods; Molecular weight; Potassium; Standard deviation
• ISSN: 0974-3618; 0974-360X; 0974-306X
• DOI: 10.5958/0974-360X.2020.00179.1

Elbasvir a NS5A inhibitor is used in combination of Grazoprevir (NS3/4A protease inhibitor) for the treatment of chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) under the trade name Zepatiar®. A mobile phase consisting of potassium dihydrogen phosphate buffer pH adjusted to 4.0: acetonitrile (40:60v/v) with a flow rate of 1.0 mL/min was used, the UV detection was carried out at 260 nm. Alkali degradation was executed by treating 0.3 mL of stock solution with 3 ml of 0.1M sodium hydroxide solution in a 10 mL volumetric flask and heated at 60°C for 24 hours in a water bath and after 24 hours the solution was neutralized with 0.1M Hydrochloric acid and the volume was madeup to 10 mL with mobile phase. Oxidative degradation was executed by treating 0.3 ml of stock solution with 1 ml of 3% hydrogen peroxide solution in a 10 mL volumetric flask and kept at room temperature for 15 min and the volume was made upto 10 mL with mobile phase.